{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:02:58Z","timestamp":1790870578412,"version":"4.1.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"abstract":"\n Importance<\/jats:title>\n Patients with head and neck cancer represent a vulnerable patient population for potential chronic opioid use. Prior institutional studies on chronic opioid use had limited sample sizes, and the incidence of and risk factors for chronic opioid use need further investigation.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the proportion of patients with opioid use and factors associated with opioid use 3 months following chemoradiation or radiation treatment for head and neck cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This single-institution cohort study at The Ohio State Comprehensive Cancer Center included patients diagnosed with nonmetastatic head and neck cancer between October 2011 and December 2023 who received definitive radiation or chemoradiation.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Receipt of definitive radiation or chemoradiation.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was opioid use 3 months after completing radiation in the entire cohort. Logistic multivariable analysis was performed to evaluate variables associated with opioid use at this time point. Secondary end points were opioid use at 6 months and time to first opioid use in an opioid-naive patient subgroup.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 789 patients met the study\u2019s inclusion criteria (639 men [81.0%]; median age, 61 years [IQR, 55-68 years]). Median follow-up was 46.7 months (IQR, 31.1-56.1 months). Between diagnosis and 6 months following radiation, 750 patients (95.1%) received prescription opioids. At 3 and 6 months following radiation, 552 (70.0%) and 373 (47.3%) patients, respectively, continued taking prescription opioids. Patients were more likely to be taking opioids at 3 months following radiation if they were former smokers (adjusted odds ratio [AOR], 1.55; 95% CI, 1.04-2.31), were referred to palliative care (AOR, 3.90; 95% CI, 2.57-6.09), or had taken opioids prior to radiation (AOR, 2.57; 95% CI, 1.82-3.63). Among 296 patients who were opioid-naive prior to radiation (37.5%), time to first opioid use was shorter for those with underweight status (adjusted hazard ratio [AHR], 7.36; 95% CI, 3.40-15.90) and those referred to palliative care (AHR, 1.42; 95% CI, 1.10-1.83). Of the opioid-naive patients, 171 (57.8%) and 112 (37.8%) continued taking opioids at 3 and 6 months following radiation, respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, 70.0% and 47.3% of patients with head and neck cancer continued taking opioids at 3 and 6 months following treatment, respectively. Factors associated with opioid use at 3 months included prior opioid use, former smoking status, and palliative care referral. These findings suggest that targeted opioid stewardship programs that consider both analgesia and long-term dependency risk are merited.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoto.2026.2536","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:42:44Z","timestamp":1790869364000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Opioid Use Following Radiation or Chemoradiation for Head and Neck Cancer"],"prefix":"10.1001","author":[{"given":"Om","family":"Desai","sequence":"first","affiliation":[{"name":"The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Kotler","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jas","family":"Virk","sequence":"additional","affiliation":[{"name":"Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Agner","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Wells","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nguyen","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darien","family":"Reed","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithik","family":"Tella","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alvarez","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Koempel","sequence":"additional","affiliation":[{"name":"The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Gogineni","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Konieczkowski","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrion","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Grecula","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Trinconi Cunha","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Bhateja","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Rocco","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin S.","family":"Kale","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Palliative Medicine, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Bonomi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dukagjin","family":"Blakaj","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"10","key":"ooi260050r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.37265","article-title":"Severe oral mucositis after intensity-modulated radiation therapy for head and neck cancer.","volume":"6","author":"Iovoli","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"ooi260050r2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","article-title":"Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline.","volume":"41","author":"Paice","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"ooi260050r3","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.3390\/curroncol30060437","article-title":"The stigma surrounding opioid use as a barrier to cancer-pain management: an overview of experiences with fear, shame, and poorly controlled pain in the context of advanced cancer.","volume":"30","author":"Harsanyi","year":"2023","journal-title":"Curr Oncol"},{"issue":"2","key":"ooi260050r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.09.023","article-title":"Risk of chronic opioid use after radiation for head and neck cancer: a systematic review and meta-analysis.","volume":"6","author":"Zayed","year":"2020","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"ooi260050r5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1177\/0194599820960137","article-title":"Implications of treatment modality on chronic opioid use following treatment for head and neck cancer.","volume":"164","author":"Bollig","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"9","key":"ooi260050r6","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.1007\/s00520-022-07155-7","article-title":"Long-term opioid use in patients treated with head and neck intensity-modulated radiotherapy.","volume":"30","author":"Zhao","year":"2022","journal-title":"Support Care Cancer"},{"issue":"1","key":"ooi260050r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ohn.70024","article-title":"Long-term opioid use after treatment of head and neck cancers: a systematic review and meta-analysis.","volume":"174","author":"Rosen","year":"2026","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"ooi260050r8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/hed.26034","article-title":"Long-term opioid use in curative-intent radiotherapy: one-year outcomes in head\/neck cancer patients.","volume":"42","author":"Schumacher","year":"2020","journal-title":"Head Neck"},{"issue":"16","key":"ooi260050r9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18051","article-title":"Opioid prescribing patterns for head and neck cancer radiation patients, with a comparison to breast cancer radiation patients.","volume":"41","author":"Lasonde","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"ooi260050r10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/bjp.2008.100","article-title":"Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.","volume":"154","author":"Christie","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"6","key":"ooi260050r11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1634\/theoncologist.2013-0001","article-title":"Predictors of long-term opioid treatment among patients who receive chemoradiation for head and neck cancer.","volume":"18","author":"Kwon","year":"2013","journal-title":"Oncologist"},{"issue":"12","key":"ooi260050r12","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1001\/jamaoto.2025.2649","article-title":"Preexisting psychiatric risk factors and any and long-term opioid use in head and neck cancer.","volume":"151","author":"Osazuwa-Peters","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"12","key":"ooi260050r13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaoto.2017.0582","article-title":"Chronic opioid use following surgery for oral cavity cancer.","volume":"143","author":"Pang","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ooi260050r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2019.03.007","article-title":"Risk of prolonged opioid use among cancer patients undergoing curative intent radiation therapy for head and neck malignancies.","volume":"92","author":"Smith","year":"2019","journal-title":"Oral Oncol"},{"issue":"9","key":"ooi260050r15","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/lary.27791","article-title":"Chronic opioid use in patients undergoing treatment for oropharyngeal cancer.","volume":"129","author":"Silver","year":"2019","journal-title":"Laryngoscope"},{"issue":"11","key":"ooi260050r16","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/jnci\/djab082","article-title":"Predictors of chronic opioid use: a population-level analysis of North Carolina cancer survivors using multi-payer claims.","volume":"113","author":"Check","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"ooi260050r17","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00683","article-title":"Associations between cancer-related financial hardship, pain, and opioid use.","volume":"OP2500683","author":"Williams","year":"2026","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"ooi260050r18","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1055\/s-0041-1741436","article-title":"Referral patterns of outpatient palliative care among the head and neck cancer population.","volume":"26","author":"Saravia","year":"2022","journal-title":"Int Arch Otorhinolaryngol"},{"issue":"7","key":"ooi260050r19","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/jnci\/djz200","article-title":"Predicting persistent opioid use, abuse, and toxicity among cancer survivors.","volume":"112","author":"Vitzthum","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"ooi260050r20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/cncr.33410","article-title":"Validation of an oncology-specific opioid risk calculator in cancer survivors.","volume":"127","author":"Riviere","year":"2021","journal-title":"Cancer"},{"key":"ooi260050r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110831","article-title":"Opioid Therapy vs. Multimodal Analgesia in Head and Neck Cancer (OPTIMAL-HN): results of a randomized clinical trial.","volume":"206","author":"Zayed","year":"2025","journal-title":"Radiother Oncol"},{"issue":"7","key":"ooi260050r23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/cncr.32676","article-title":"A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer.","volume":"126","author":"Hermann","year":"2020","journal-title":"Cancer"},{"issue":"5","key":"ooi260050r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12900","article-title":"Association of gabapentin use with pain control and feeding tube placement among patients with head and neck cancer receiving chemoradiotherapy.","volume":"5","author":"Ma","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"ooi260050r25","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3390\/cancers15072003","article-title":"Prophylactic high-dose gabapentin reduces opiate use during radiation therapy for head and neck squamous cell carcinoma.","volume":"15","author":"Qiu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ooi260050r27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1145323","article-title":"A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer.","volume":"13","author":"Horinouchi","year":"2023","journal-title":"Front Oncol"},{"key":"ooi260050r28","doi-asserted-by":"publisher","DOI":"10.1177\/20503121251339581","article-title":"Clinical pharmacists and nurses in the management of oral mucositis in head and neck cancer patients during antineoplastic therapy: a scoping review.","volume":"13","author":"Kaisha","year":"2025","journal-title":"SAGE Open Med"},{"issue":"5","key":"ooi260050r29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"ooi260050r30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO-25-00835","article-title":"Induction nivolumab before chemoradiation in high-risk human papillomavirus-driven oropharynx cancers: IMMUNEBOOST-HPV, a multicenter randomized phase II trial.","volume":"44","author":"Mirghani","year":"2026","journal-title":"J Clin Oncol"},{"issue":"5","key":"ooi260050r31","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/bcp.16377","article-title":"Clinical relevance of immune checkpoint inhibitors for the analgesic effect of opioids: a retrospective propensity score analysis.","volume":"91","author":"Sumimoto","year":"2025","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"ooi260050r32","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41416-024-02802-8","article-title":"Prevalence of opioid misuse in patients with cancer: a systematic review and meta-analysis.","volume":"131","author":"Ako","year":"2024","journal-title":"Br J Cancer"},{"issue":"8","key":"ooi260050r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13605","article-title":"National patterns in prescription opioid use and misuse among cancer survivors in the United States.","volume":"3","author":"Jairam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"ooi260050r34","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jamaoto.2024.3233","article-title":"Comorbid depression in patients with head and neck cancer compared with other cancers.","volume":"150","author":"Martinez","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"6","key":"ooi260050r35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons With Harmful Alcohol Consumption\u2013II.","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"issue":"1","key":"ooi260050r36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13014-025-02749-x","article-title":"Financial toxicity on treatment outcomes in head and neck cancer patients undergoing radiation therapy.","volume":"20","author":"Harada","year":"2025","journal-title":"Radiat Oncol"},{"key":"ooi260050r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105328","article-title":"Patterns of alcohol use among early head and neck cancer survivors: a cross-sectional survey study using the Alcohol Use Disorders Identification Test (AUDIT).","volume":"119","author":"Teckie","year":"2021","journal-title":"Oral Oncol"},{"key":"ooi260050r21","unstructured":"National Comprehensive Cancer Network. Adult cancer pain: version 1. 2026. Accessed March 30, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pain.pdf"},{"key":"ooi260050r26","unstructured":"High-dose prophylactic gabapentin (HOPE) vs placebo to prevent opioid use for oral mucositis pain during concurrent chemoradiation for head and neck cancer (HOPE). ClinicalTrials.gov identifier: NCT06992427. Updated May 11, 2026. Accessed August 20, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06992427"}],"container-title":["JAMA Otolaryngology\u2013Head & Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2854687\/jamaotolaryngology_desai_2026_oi_260050_1790260372.41086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:42:47Z","timestamp":1790869367000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2854687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2026.2536","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}